Evidence map›Paper›PMID 39932221›Full record

ArticleFuture oncology (London, England)2025

SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.

Gregory M Cote, Sant P Chawla, George Demetri, Bernd Kasper, Robin L Jones, Javier Martin Broto, Joseph Wooley, Mia C Weiss, Salvatore Tafuto, Giuseppe Badalamenti and 9 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Identification of a novelTherapeutic advances in medical oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gregory M CoteCenter for Sarcoma and Connective Tissue Oncology, Mass General Cancer Center, Boston, Massachusetts, USA.ORCID 0000-0003-0181-886X
Sant P ChawlaCancer Center of Southern California, Sarcoma Oncology Center, Santa Monica, California, USA.
George DemetriSarcoma Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Bernd KasperSarcoma Unit, Mannheim University Medical Center (UMM), Mannheim, Germany.
Robin L JonesDepartment of Medical Oncology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
Javier Martin BrotoDepartment of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Joseph WooleyDepartment of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio, USA.
Mia C WeissDivision of Medical Oncology, Washington University School of Medicine in St. Louis, St Louis, Missouri, USA.
Salvatore TafutoSarcomas and Rare Tumors Unit, Istituto Nazionale dei Tumori IRCCS Fondazione "G Pascale", Napoli, Italy.
Giuseppe BadalamentiDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, A. O. U. P. Paolo Giaccone, Palermo, Italy.
Irene CarrascoDepartment of Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Paloma PeinadoHM CIOCC MADRID (Centro Integral Oncológico Clara Campal), HM Sanchinarro, Madrid, Spain.
Jean-Yves BlayDepartment of Medical Oncology, Centre Léon Bérard, Lyon, France.
Gaston BoggioClinical R&D, PharmaMar, Colmenar, Viejo, Spain.
Cristian FernandezClinical R&D, PharmaMar, Colmenar, Viejo, Spain.
Antonio NietoClinical R&D, PharmaMar, Colmenar, Viejo, Spain.
Carmen KahattClinical R&D, PharmaMar, Colmenar, Viejo, Spain.
Vicente AlfaroClinical R&D, PharmaMar, Colmenar, Viejo, Spain.ORCID 0000-0002-0150-2390
Axel Le CesneDepartment of Medical Oncology, Institut Gustave Roussy, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous phase I/II trials indicate promising activity of lurbinectedin plus doxorubicin (DOX) in leiomyosarcoma (LMS). We describe here the rationale and design of SaLuDo, an open label, randomized, multicenter, seamless phase IIb/III study to evaluate the antitumor activity and safety of lurbinectedin plus DOX

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarbolinesLeiomyosarcomaAdultAgedCarbazolesClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDoxorubicinFemaleHeterocyclic Compounds, 4 or More RingsHumansMaleMiddle AgedMulticenter Studies as TopicProgression-Free SurvivalCarbazolesCarbolinesDoxorubicinHeterocyclic Compounds, 4 or More RingsPM 01183doxorubicinLeiomyosarcomalurbinectedinoverall survivalphase IIb/IIIprogression-free survivalseamless adaptive design

Identifiers

PMID39932221
PMCPMC11938983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.